180
DEAD

Serial Number

97255702

Owner

180 Life Sciences Corp.

Attorney

Eric Eisenberg

Filing Date

Feb 7, 2022

Add to watchlist:

No watchlists yet
View on USPTO

180 Trademark

Serial Number: 97255702

180 is a trademark filed by 180 Life Sciences Corp. on February 7, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

180 Life Sciences Corp. (4 trademarks)

Building 4, Suite 200
Palo Alto, CA 94306

Entity Type: 03

Trademark Details

Filing Date

February 7, 2022

Registration Date

Not Registered

Goods & Services

Analgesic preparations; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammation; Pharmaceutical preparations for the treatment of Dupuytren's disease; Pharmaceutical preparations for the treatment of frozen shoulder; Pharmaceutical preparations for the treatment of post-operative delirium; Pharmaceutical preparations for the treatment of post-operative cognitive deficit; Pharmaceutical preparations for the treatment of post-operative cognitive decline; Pharmaceutical preparations for the treatment of non-alcoholic steatohepatitis; Pharmaceutical preparations for the treatment of fibrosis; Pharmaceutical preparations for the treatment of liver fibrosis; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of ulcerative colitis; Pharmaceutical preparations for the treatment of anxiety; Pharmaceutical preparations for the treatment of type 1 diabetes; Pharmaceutical preparations for the treatment of type 2 diabetes; Pharmaceutical preparations for inhibition of tumor necrosis factor (TNF); Pharmaceutical preparations for interacting with nicotine receptors; Pharmaceutical preparations for synthetically simulating non-psychoactive effects of cannabidiol (CBD); Pharmaceutical preparations for liver regeneration; Pharmaceutical preparations for regenerative therapy; Pharmaceutical preparations for acting as an alpha-7nAChR agonist

Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the pharmaceutical and biotechnology fields; Scientific research for medical purposes in the field of inflammatory diseases; Scientific research for medical purposes in the field of treatment of inflammation; Scientific research for medical purposes in the field of Dupuytren's disease; Scientific research for medical purposes in the field of frozen shoulder; Scientific research for medical purposes in the field of post-operative delirium, post-operative cognitive deficit, and post-operative cognitive decline; Scientific research for medical purposes in the field of non-alcoholic steatohepatitis; Scientific research for medical purposes in the field of fibrosis; Scientific research for medical purposes in the field of liver fibrosis; Scientific research for medical purposes in the field of arthritis; Scientific research for medical purposes in the field of pain treatment; Scientific research for medical purposes in the field of ulcerative colitis; Scientific research for medical purposes in the field of treatment of anxiety; Scientific research for medical purposes in the field of inhibition of tumor necrosis factor (TNF) and anti-TNF pharmaceuticals; Scientific research for medical purposes in the field of interactions with nicotine receptors; Scientific research for medical purposes in the field of synthetic simulation of non-psychoactive effects of cannabidiol (CBD); Scientific research for medical purposes in the field of synthetic cannabidiol (CBD) analogs; Scientific research for medical purposes in the field of type 1 diabetes; Scientific research for medical purposes in the field of type 2 diabetes; Scientific research for medical purposes in the field of liver regeneration; Scientific research for medical purposes in the field of regenerative therapy; Scientific research for medical purposes in the field of alpha-7nAChR agonists

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jun 27, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jun 27, 2024 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 25, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 25, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 25, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 17, 2024 DOCK
ASSIGNED TO EXAMINER
Dec 6, 2023 DOCK
ASSIGNED TO EXAMINER
Dec 4, 2023 DOCK
ASSIGNED TO EXAMINER
Jul 18, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 12, 2022 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 11, 2022 NWOS
NEW APPLICATION ENTERED
Feb 10, 2022 NWAP